Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HCWB by emailGet an email when HCWB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HCWB, unsubscribe in one click. Privacy
📣 What HCWB Says Is Next
first half of 2027 · “This clinical trial is on track to initiate in the first half of 2027, provided we secured FDA authorization.”
Company press release, Aug 14, 2026 · SEC filing
fourth quarter of 2026 · “The Company remains on track for a full Phase 1 clinical data readout in the fourth quarter of 2026.”
Company press release, Aug 14, 2026 · SEC filing
fourth quarter of 2026 · “With continued patient enrollment, the full Phase 1 human data readout is expected in the fourth quarter of 2026.”
Company press release, May 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HCWB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCWB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.